Literature DB >> 24555302

New therapeutic potentials of milk thistle (Silybum marianum).

Natasa Milić1, Natasa Milosević1, Ljiljana Suvajdzić1, Marija Zarkov2, Ludovico Abenavoli3.   

Abstract

Silymarin is a bioflavonoid complex extract derived from dry seeds of Milk thistle [(Silybum marianum(L.) Gaemrnt. (Fam. Asteraceae/Compositaceae)] whose hepatoprotective effect has clinically been proved. Low toxicity, favorable pharmacokinetics, powerful antioxidant, detoxifying, preventive, protective and regenerative effects and side effects similar to placebo make silymarin extremely attractive and safe for therapeutic use. The medicinal properties of silymarin and its main component silibinin have been studied in the treatment of Alzheimer's disease, Parkinson's disease, sepsis, burns, osteoporosis, diabetes, cholestasis and hypercholesterolemia. Owing to its apoptotic effect, without cytotoxic effects, silymarin possesses potential applications in the treatment of various cancers. Silymarin is being examined as a neuro-, nephro- and cardio-protective in the damage of different etiologies due to its strong antioxidant potentials. Furthermore, it has fetoprotective (against the influence of alcohol) and prolactin effects and is safe to be used during pregnancy and lactation. Finally, the cosmetics industry is examining the antioxidant and UV-protective effects of silymarin. Further clinical studies and scientific evidence that silymarin and silibinin are effective in the therapy of various pathologies are indispensable in order to confirm their different flavonolignan pharmacological effects.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24555302

Source DB:  PubMed          Journal:  Nat Prod Commun        ISSN: 1555-9475            Impact factor:   0.986


  14 in total

1.  Addition of silymarin to renin-angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trial.

Authors:  Luminita Voroneanu; Dimitrie Siriopol; Raluca Dumea; Silvia Badarau; Mehmet Kanbay; Baris Afsar; Cristina Gavrilovici; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2017-09-25       Impact factor: 2.370

Review 2.  Targeting drivers of melanoma with synthetic small molecules and phytochemicals.

Authors:  Leah Ray Strickland; Harish Chandra Pal; Craig A Elmets; Farrukh Afaq
Journal:  Cancer Lett       Date:  2015-01-15       Impact factor: 8.679

Review 3.  Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.

Authors:  Tomas Koltai; Larry Fliegel
Journal:  J Evid Based Integr Med       Date:  2022 Jan-Dec

Review 4.  A Comprehensive Review of the Cardiovascular Protective Properties of Silibinin/Silymarin: A New Kid on the Block.

Authors:  Nikolaos P E Kadoglou; Chrystalla Panayiotou; Michail Vardas; Nikolaos Balaskas; Nikolaos G Kostomitsopoulos; Alexandra K Tsaroucha; Georgia Valsami
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-27

Review 5.  Botanicals and Their Bioactive Phytochemicals for Women's Health.

Authors:  Birgit M Dietz; Atieh Hajirahimkhan; Tareisha L Dunlap; Judy L Bolton
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

6.  Silibinin, a natural flavonoid, induces autophagy via ROS-dependent mitochondrial dysfunction and loss of ATP involving BNIP3 in human MCF7 breast cancer cells.

Authors:  Kai Jiang; Wei Wang; Xin Jin; Zhaoyang Wang; Zhiwei Ji; Guanmin Meng
Journal:  Oncol Rep       Date:  2015-04-17       Impact factor: 3.906

Review 7.  Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives.

Authors:  Peter F Surai
Journal:  Antioxidants (Basel)       Date:  2015-03-20

8.  Silymarin Ameliorates Diabetes-Induced Proangiogenic Response in Brain Endothelial Cells through a GSK-3β Inhibition-Induced Reduction of VEGF Release.

Authors:  Ahmed Alhusban; Enaam Alkhazaleh; Tamam El-Elimat
Journal:  J Diabetes Res       Date:  2017-10-25       Impact factor: 4.011

9.  Intraperitoneal Administration of Silymarin Protects End Organs from Multivisceral Ischemia/Reperfusion Injury in a Rat Model.

Authors:  Aydemir Koçarslan; Sezen Koçarslan; Mehmet Salih Aydin; Şamil Gunay; Mahmut Alp Karahan; Abdullah Taşkın; Murat Üstunel; Nurten Aksoy
Journal:  Braz J Cardiovasc Surg       Date:  2016 Nov-Dec

Review 10.  Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson's disease models.

Authors:  Palanivel Ganesan; Hyun-Myung Ko; In-Su Kim; Dong-Kug Choi
Journal:  Int J Nanomedicine       Date:  2015-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.